Loading...
•
Mar 31
Halozyme Q1 2025 Earnings Report
Halozyme reported strong Q1 2025 results with substantial year-over-year growth in revenue and earnings.
Key Takeaways
Halozyme posted a 35% increase in total revenue for Q1 2025, driven by strong royalty income, and achieved significant growth in net income and EPS.
Total revenue grew to $264.9 million, a 35% increase from Q1 2024.
Net income rose 54% year-over-year to $118.1 million.
Adjusted EBITDA reached $162 million, up from $115.7 million last year.
GAAP diluted EPS was $0.93, while non-GAAP diluted EPS was $1.11.
Halozyme
Halozyme
Halozyme Revenue by Segment
Revenue by Segment
Royalties Revenue
CapyFin.comUnder Collaborative Agreements Revenue
CapyFin.com Forward Guidance
Halozyme raised its full-year 2025 financial guidance, anticipating higher total revenue, royalty revenue, adjusted EBITDA, and non-GAAP EPS.
Positive Outlook
- Total revenue guidance increased to $1.2–1.28 billion
- Royalty revenue guidance raised to $750–785 million
- Adjusted EBITDA guidance lifted to $790–840 million
- Non-GAAP EPS guidance raised to $5.30–5.70
- New $250 million share repurchase announced
Challenges Ahead
- Guidance reflects current tariff impacts
- No guidance provided on potential litigation outcomes
- Does not factor in effects of future share repurchases on EPS
- No specific product-level revenue guidance disclosed
- Uncertainty remains on timing of new approvals and reimbursements